Velcade: Clinical Trials

271 trials of Velcade, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

154 completed, 59 terminated, 21 unknown, 14 active not recruiting. 271 Phase 2, 50 Phase 1, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2271Completed 154, Terminated 59, Unknown 21, Active not recruiting 14, Withdrawn 13, Recruiting 8, Not yet recruiting 2
Phase 150Completed 30, Terminated 8, Unknown 5, Active not recruiting 3, Withdrawn 3, Not yet recruiting 1
Phase 33Not yet recruiting 1, Terminated 1, Unknown 1

Follow Velcade: new trials by email Literature Review of Velcade trials Research Report on Velcade

Trials (filtered) newest first · largest first

All 271 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma
Isatuximab, Iberdomide, Bortezomib - Newly Diagnosed Multiple Myeloma
Phase 1 / Phase 2Not yet recruitingDana-Farber Cancer Institute882026-09-032026-09-03
Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma
Phase 2 / Phase 3Not yet recruitingChildren's Oncology Group17082026-08-282026-07-30
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Belantamab mafodotin, Dexamethasone, Pomalidomide - Multiple Myeloma
Phase 2RecruitingGlaxoSmithKline2002026-04-152026-08-25
Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure
Cyclophosphamide, Bortezomib (VELCADE), Dexamethasone - Myeloma Multiple
Phase 2RecruitingEastern Cooperative Oncology Group742026-03-052026-11-16
Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
Iberdomide, Bortezomib, Dexamethasone - Multiple Myeloma
Phase 2RecruitingCanadian Myeloma Research Group752024-12-122026-08-31
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Multiple Myeloma
Phase 2Active not recruitingNational Cancer Institute (NCI)582024-07-232026-09-25
Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis
Bortezomib, Pomalidomide, Dexamethasone - Systemic Amyloidosis
Phase 2RecruitingJin Lu, MD402024-05-062024-12-30
Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS
Daratumumab, Bortezomib, Lenalidomide - Multiple Myeloma
Phase 2UnknownStichting European Myeloma Network2002023-11-232024-04-23
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
Daratumumab, Carfilzomib, Lenalidomide - Multiple Myeloma, Primary Plasma Cell Leukemia
Phase 2RecruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology542023-10-202025-04-16
CURATE.AI Optimized Modulation for Multiple Myeloma
Bortezomib, Cyclophosphamide, Dexamethasone - Multiple Myeloma
Phase 2 / Phase 3UnknownNational University Hospital, Singapore202023-09-102023-09-06
Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial
Bortezomib, Dexamethasone, Pelareorep - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Phase 1 / Phase 2Active not recruitingUniversity of Southern California102022-10-072026-05-13
Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
Bortezomib, Daratumumab, Dexamethasone - Plasma Cell Myeloma
Phase 1 / Phase 2Active not recruitingMayo Clinic492022-08-112026-10-16
Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma
Selinexor, Bortezomib, Lenalidomide - Multiple Myeloma
Phase 1 / Phase 2UnknownXia Zhongjun422022-07-252024-06-17
Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency
Bortezomib, Isatuximab, Cyclophosphamide - Multiple Myeloma
Phase 2RecruitingMedical College of Wisconsin412021-11-022026-01-28
Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients
Selinexor 20 MG Oral Tablet, Bortezomib Injection, Lenalidomide capsule - Multiple Myeloma
Phase 2Active not recruitingIda Bruun Kristensen502021-08-182026-10-16
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
Acalabrutinib, Bortezomib, Cyclophosphamide - Mantle Cell Lymphoma
Phase 2Active not recruitingAcademic and Community Cancer Research United412021-08-032026-08-25
DARA RVD For High Risk SMM
Daratumumab, Bortezomib, Lenalidomide - High-risk Smoldering Multiple Myeloma, Multiple Myeloma
Phase 2Active not recruitingOmar Nadeem, MD612021-03-082026-07-02
VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma
bortezomib, Lenalidomide, Dexamethasone - Myeloma, Newly Diagnosed
Phase 2UnknownSun Yat-sen University502020-09-252023-06-18
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
Selinexor, Dexamethasone, Bortezomib - Multiple Myeloma, Refractory
Phase 2RecruitingKaryopharm Therapeutics Inc1272020-07-012026-10-29
A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment
Bortezomib Injection - Myeloma, Myeloma Multiple
Phase 2TerminatedAHS Cancer Control Alberta392020-05-292026-10-28

Showing 20 of 271. Sign in to see all of them.

Conditions studied

Multiple Myeloma (122)  ·  Lymphoma, Mantle-Cell (24)  ·  Recurrence (19)  ·  Lymphoma (17)  ·  Lymphoma, Non-Hodgkin (16)  ·  Lymphoma, Follicular (15)  ·  Neoplasms, Plasma Cell (14)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (12)  ·  Leukemia, Myeloid, Acute (10)  ·  Lymphoma, Large B-Cell, Diffuse (10)  ·  Waldenstrom Macroglobulinemia (9)  ·  Carcinoma, Non-Small-Cell Lung (8)  ·  Leukemia (7)  ·  Immunoglobulin Light-chain Amyloidosis (6)  ·  Amyloidosis (5)

Sponsors

National Cancer Institute (NCI) (41)  ·  M.D. Anderson Cancer Center (13)  ·  Dana-Farber Cancer Institute (11)  ·  Millennium Pharmaceuticals, Inc. (8)  ·  University of Arkansas (8)  ·  Mayo Clinic (7)  ·  Duke University (5)  ·  Emory University (4)  ·  Fred Hutchinson Cancer Center (4)  ·  H. Lee Moffitt Cancer Center and Research Institute (4)  ·  Northwestern University (4)  ·  PETHEMA Foundation (4)  ·  SCRI Development Innovations, LLC (4)  ·  Hackensack Meridian Health (3)  ·  Korean Multiple Myeloma Working Party (3)

Countries

United States (195)  ·  Germany (14)  ·  Canada (13)  ·  France (12)  ·  Greece (12)  ·  Spain (12)  ·  Italy (11)  ·  China (10)  ·  South Korea (10)  ·  United Kingdom (8)  ·  Australia (7)  ·  Netherlands (7)  ·  Czechia (6)  ·  Belgium (5)  ·  Brazil (4)

Top investigators

Irene Ghobrial, MD (4)  ·  Maurizio Zangari, MD (3)  ·  E. Steve Woodle, MD (2)  ·  Jae Hoon Lee, M.D. (2)  ·  James R Berenson, MD (2)  ·  Joanne Filicko-O'Hara, MD (2)  ·  John Koreth, MBBS, DPhil (2)  ·  Leona Holmberg (2)  ·  Melissa Alsina, MD (2)  ·  Paul Richardson, MD (2)  ·  Shaji Kumar, M.D. (2)  ·  Vaishali Sanchorawala, MD (2)  ·  Ajay Nooka, MD, MPH (1)

Results publications

PMID 33357481, PMID 29567784, PMID 36184192, PMID 40501401, PMID 15613697, PMID 18327587, PMID 19498019, PMID 19528374, PMID 19692142, PMID 19860608, PMID 19884643, PMID 20012045, PMID 20142586, PMID 20582937, PMID 20661232, PMID 20956803, PMID 21239695, PMID 21241279, PMID 21345726, PMID 21562045, PMID 21596852, PMID 21911830, PMID 21990396, PMID 22535574, PMID 22653976, PMID 22674807, PMID 22689675, PMID 22733020, PMID 22773122, PMID 23305732, PMID 23603914, PMID 23940282, PMID 24048792, PMID 24458437, PMID 24526575, PMID 24890858, PMID 25039282, PMID 25202139, PMID 25294016, PMID 25572917, PMID 25777345, PMID 25813205, PMID 25824111, PMID 25833390, PMID 25911554, PMID 26055298, PMID 26139427, PMID 26232170, PMID 26248505, PMID 26285768

NIH funding

U10CA021115 (7), U10CA031946 (7), N01CM62205 (4), U10CA032102 (4), U10CA180821 (4), N01CM62204 (3), P30CA015704 (3), U10CA098543 (3), 2005 (2), 2008 (2), 2015 (2), 2016 (2), N01CM17003 (2), N01CM62203 (2), N01CM62208 (2)